Fulgent Genetics (FLGT) EBT Margin (2015 - 2026)

Fulgent Genetics has disclosed EBT Margin across 12 years of filings, most recently posting 36.52% for Q1 2026.

• EBT Margin for Q1 2026 came in at 36.52%, down 2056.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.49% (up 569.0% YoY), and the FY2025 annual result was 2.56%, up 1395.0% from the prior year.
• EBT Margin came in at 36.52% for Q1 2026 at Fulgent Genetics, down from 8121.25% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 8121.25% in Q4 2025 to a low of 36.52% in Q1 2026.
• The 5-year median for EBT Margin is 12.36% (2024), against an average of 499.98%.
• Across the five-year window, EBT Margin slumped 9488 bps in 2023 and soared 812506 bps in 2025, its largest moves.
• Fulgent Genetics' EBT Margin stood at 1.66% in 2022, then surged by 93 bps to 3.22% in 2023, then plunged by 218 bps to 3.81% in 2024, then soared by 213385 bps to 8121.25% in 2025, then slumped by 100 bps to 36.52% in 2026.
• The last three EBT Margin figures came in at 36.52% (Q1 2026), 8121.25% (Q4 2025), and 8.93% (Q3 2025), per Business Quant data.